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Objectives: To compare the frequency of area postrema syndrome (APS) in adults with
anti-aquaporin-4 (AQP4) and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies.
Methods: APS is defined as acute or subacute, single or combined, episodic or
constant nausea, vomiting, or hiccups, persisting for at least 48 h, which cannot be
attributed to any other etiology. The presence of APS was investigated in 274 adults
with AQP4 antibodies and 107 adults with MOG antibodies from 10 hospitals.
Results: The study population comprised Korean adults (≥18 years). At the time of
disease onset, 14.9% (41/274) adults with AQP4 antibodies had APS, while none of
the participants with MOG antibodies developed APS (p < 0.001). During the course of
the disease, 17.2% (47/274) adults with AQP4 antibodies had APS in contrast to 1.9%
(2/107) adults with MOG antibodies with APS (p < 0.001).
Conclusions: APS, one of the core clinical characteristics of individuals with AQP4
antibodies, is an extremely rare manifestation in Korean adults with MOG antibodies.
Keywords: area postrema syndrome, aquaporin-4 antibody, MOG antibody, neuromyelitis optica spectrum
disorder, diagnosis
INTRODUCTION
Individuals with anti-aquaporin-4 (AQP4) antibodies and anti-myelin oligodendrocyte
glycoprotein (MOG) antibodies were previously grouped under the umbrella term neuromyelitis
optica spectrum disorder (NMOSD), as they shared two cardinal clinical manifestations, optic
neuritis and longitudinally extensive transverse myelitis. However, the two conditions are
now considered distinct entities based on differences in histopathology, plausible underlying
pathogenic mechanisms, clinical courses, treatment responses, and some distinguishing clinical
manifestations (1–3).
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Area postrema syndrome (APS), one of the core clinical
characteristics described in the 2015 diagnostic criteria for
NMOSD, is defined as intractable nausea, vomiting, or hiccups,
which persist for at least 48 h (4, 5). Area postrema is located
in the dorsal tegmentum of the medulla, an AQP4-rich region,
which is often affected in individuals with AQP4 antibodies
(6–8). In contrast to the preferential expression of AQP4 in
certain regions of the central nervous system (CNS) (9), MOG is
expressed throughout the CNS. As such, APS is not particularly
expected in individuals with MOG antibodies, unlike those
with AQP4 antibodies. This study evaluated the value of APS
as a clinical characteristic in differentiating individuals with
AQP4 antibodies from those with MOG antibodies in a large
Korean cohort.
METHODS
The study included 298 participants with AQP4 antibodies
from National Cancer Center (NCC) NMOSD cohort and 124
participants with MOG antibodies from 10 referral hospitals
between 2005 and 2019. Four non-Koreans and 37 participants
(21 with AQP4 antibodies and 16 withMOG antibodies) with the
age of onset below 18 years were excluded. Finally, the frequency
of APS was evaluated in 274 participants with AQP4 antibodies
and 107 participants with MOG antibodies, by retrospective
reviewing of the medical records based on physicians’ active
questioning regarding APS. APS was defined as per the following
recently proposed criteria: (1) acute or subacute, single or
combined, episodic or constant nausea, vomiting, or hiccups,
(2) persistent for at least 48 h, (3) without a known etiology (5).
The serostatus of AQP4 and MOG antibodies was assessed using
live cell-based assays performed at the NCC and Seoul National
University Hospital (10–12).
Fisher’s exact test was used to compare the presence of APS
between the two groups. The study protocol was approved by the
institutional review boards of the NCC.
RESULTS
Demographics
The female-to-male ratio was 7.1:1 and 1.1:1 in participants
with AQP4 antibodies and MOG antibodies, respectively. All
the participants enrolled in this study were Korean. The mean
age at disease onset was 37 years (range, 18–80 years) and 36
years (range, 18–72 years) for participants with AQP4 and MOG
antibodies, respectively. The mean disease duration was 11 years
(range, 1–36 years) and 7 years (range, 1–30 years) in participants
with AQP4 and MOG antibodies, respectively. The mean follow-
up period was 6 years (range, 1–14 years) and 4 years (range,
1–16 years) in individuals with AQP4 and MOG antibodies,
respectively. The mean total number of attacks was 6 (range, 1–
36) and 3 (range, 1–12) in participants with AQP4 and MOG
antibodies, respectively.
Presence of APS
The initial manifestations of APS were observed in 41 (14.9%)
of 274 participants with AQP4 antibodies, while none were
observed in participants with MOG antibodies (p < 0.001).
During the course of the disease, APS occurred in 47 of
274 participants (17.2%) with AQP4 antibodies, while only 2
of 107 participants (1.9%) with MOG antibodies experienced
APS (p < 0.001). After considering the number of attacks,
the significant difference in frequency of APS remained [2.8%
(47/1686) vs. 0.6% (2/310), number of APS/total attacks, p
= 0.026]. One of the two participants with MOG antibodies
reported a 1-week history of constant nausea associated with
acute disseminated encephalomyelitis (ADEM)-like lesions in
the bilateral cerebral hemispheres and poorly demarcated dorsal
midbrain and pontine lesions around the fourth ventricle
(Figure 1). The other one with MOG antibody had episodic
nausea and vomiting for 2 days with ADEM-like patch lesions in
the left frontal lobe, basal ganglia, thalamus, and right external
capsule (Figure 2). Four other patients with MOG antibodies
presented with episodic or constant nausea/vomiting (n = 3), or
hiccups (n = 1), but their symptoms did not persist for at least
48 h. Of six participants with AQP4 antibodies who developed
APS after their initial presentation, four showed isolated APS
as main phenotype of relapse (two of four with brain MRI at
the time of relapse had no or only non-specific brain lesion
except area postrema lesion). The remaining two participants
with AQP4 antibodies experienced APS with optic neuritis (n =
1) or myelitis (n= 1) at the time of relapse.
Discussions
In contrast to AQP4 antibody-positive NMOSD, APS was rarely
observed in Korean adults with MOG antibodies: none at onset
and only 1.9% during the course of the disease. As the first
manifestation, APS was exclusively observed in Korean adults
with AQP4 antibodies while two adults with MOG antibodies
had APS in the context of ADEM in their subsequent attacks.
None of the participants withMOG antibodies had APS with area
postrema lesion.
Two previous studies conducted in Western countries
reported similar findings in both children and adults; APS at
disease onset was rare in children with MOG antibodies (3.8%,
1/26) compared to those with AQP4 antibodies (50%, 4/8) (13),
and APS presented only as a subsequent attack (2%, 1/50) in
adults with MOG antibodies (14). Most recent article published
after the completion of our study reported that the frequency
of APS in the context of ADEM was 8.5% (10/117), while APS
associated with area postrema lesion was extremely rare (0.9%,
1/117) in adults with MOG antibodies (15). Another recent study
focused on magnetic resonance imaging findings also showed
that area postrema lesions were uncommon in individuals with
MOG antibodies (7%, 1/14) compared to those with AQP4
antibodies (50%, 8/16) (16). However, one study reported a
relatively high frequency of APS (14.6%, 11/75) in a Caucasian
and adult predominant cohort with MOG antibodies (17). Of
note, the duration of patients’ symptoms suggestive of APS in this
study is uncertain and may have not persisted for at least 48 h, as
defined by the criteria (5, 17).
Owing to the retrospective design of the current study based
on a cohort of referral hospitals, inevitable potential recall and
selection bias in the evaluation of APS might be present; larger
prospective population-based studies are warranted to confirm
our findings.
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FIGURE 1 | Participant 1 shows high fluid-attenuated inversion recovery (FLAIR) signal abnormalities in (A,B) bilateral cerebral hemispheres, (C) poorly demarcated
dorsal midbrain, and (D,E) pontine lesions around the fourth ventricle. (F) No area postrema lesion is observed.
FIGURE 2 | Participant 2 had high FLAIR signal abnormalities in the (A) left frontal lobe, (B–E) basal ganglia, (C) thalamus, right external capsule, and (D) right frontal
lobe. (F) No area postrema lesion is observed.
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In conclusion, APS is a rare clinical feature in Korean
adults with MOG antibodies and a reliable core clinical
characteristic in those with AQP4 antibodies. Our findings
suggest that a comprehensive evaluation of APS could be helpful
in distinguishing individuals with AQP4 antibodies from those
with MOG antibodies.
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